PCM
MPLT

Penserra Capital Management’s MapLight Therapeutics MPLT Stock Holding History

Penserra Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38K Buy
+1,088
New +$31.3K ﹤0.01% 822

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Penserra Capital Management's MPLT Position: Q2 2026 in Review

Penserra Capital Management opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 1,088 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings.

106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Penserra Capital Management held 1,088 shares of MapLight Therapeutics worth $38K as of Q2 2026.
  • MapLight Therapeutics was a new Penserra Capital Management position in Q2 2026.
  • MapLight Therapeutics made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #822 holding.
  • 106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.